What is Bionano Genomics Inc's earnings per share (EPS)?

Bionano Genomics Inc (BNGO) reported diluted earnings per share of $-4.85 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Bionano Genomics Inc Financials

BNGO

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Bionano Genomics Inc (BNGO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BNGO FY2025 2026-05-13

A cost-and-margin reset sharply reduced accounting losses and cash burn, but external financing still carried FY2025 liquidity.

From FY2024 to FY2025, gross margin jumped from 1.2% to 46.3% even as revenue fell. At the same time, operating cash burn narrowed from -$68.9M to -$16.3M, pointing to a cost-structure reset and better unit economics rather than a sales-led recovery or simple scale benefit.

The current ratio improved to 2.0x, but cash on hand was only $3.0M, so reported liquidity still rested heavily on non-cash current assets. With operating cash flow at -$16.3M and financing bringing in $24.0M, the business was still relying on outside capital to cover its cash needs.

The balance sheet looks less strained than a year earlier because total liabilities fell from $41.3M to $29.2M. Equity rose to $44.4M, pushing debt-to-equity down to 0.7x and making the capital structure less liability-heavy, even though it is still not cash-rich.

Financial Health Signals

Financial Profile 23/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Bionano Genomics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Bionano Genomics Inc has an operating margin of -117.0%, meaning the company retains $-117 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -337.9% the prior year.

Growth

Bionano Genomics Inc's revenue declined 7.4% year-over-year, from $30.8M to $28.5M. This contraction results in a growth score of 15/100.

Leverage

Bionano Genomics Inc carries a low D/E ratio of 0.66, meaning only $0.66 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 89/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Bionano Genomics Inc's current ratio of 1.98 indicates adequate short-term liquidity, earning a score of 36/100. The company can meet its near-term obligations, though with limited headroom.

Returns

Bionano Genomics Inc generates a -59.4% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -316.7% the prior year.

Piotroski F-Score Neutral

4/9

Bionano Genomics Inc passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

0.62x

For every $1 of reported earnings, Bionano Genomics Inc generates $0.62 in operating cash flow (-$16.3M OCF vs -$26.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$28.5M

YoY-7.4%

5Y CAGR+27.4%

Bionano Genomics Inc generated $28.5M in revenue in fiscal year 2025. This represents a decrease of 7.4% from the prior year.

EBITDA

-$23.8M

YoY+73.5%

Bionano Genomics Inc's EBITDA was -$23.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 73.5% from the prior year.

Net Income

-$26.4M

YoY+76.4%

Bionano Genomics Inc reported -$26.4M in net income in fiscal year 2025. This represents an increase of 76.4% from the prior year.

EPS (Diluted)

$-4.85

Bionano Genomics Inc earned $-4.85 per diluted share (EPS) in fiscal year 2025. This represents an increase of 94.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$3.0M

YoY-67.4%

5Y CAGR-40.0%

Bionano Genomics Inc held $3.0M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

11M

Bionano Genomics Inc had 11M shares outstanding in fiscal year 2025. This represents an increase of 475.8% from the prior year.

Margins & Returns

Gross Margin

46.3%

YoY+45.0pp

5Y CAGR+13.6pp

Bionano Genomics Inc's gross margin was 46.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 45.0 percentage points from the prior year.

Operating Margin

-117.0%

YoY+220.9pp

5Y CAGR+336.4pp

Bionano Genomics Inc's operating margin was -117.0% in fiscal year 2025, reflecting core business profitability. This is up 220.9 percentage points from the prior year.

Net Margin

-92.6%

YoY+271.4pp

5Y CAGR+390.8pp

Bionano Genomics Inc's net profit margin was -92.6% in fiscal year 2025, showing the share of revenue converted to profit. This is up 271.4 percentage points from the prior year.

Return on Equity

-59.4%

YoY+257.2pp

5Y CAGR+57.8pp

Bionano Genomics Inc's ROE was -59.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 257.2 percentage points from the prior year.

Capital Allocation

R&D Spending

$11.4M

YoY-54.1%

5Y CAGR+2.1%

Bionano Genomics Inc invested $11.4M in research and development in fiscal year 2025. This represents a decrease of 54.1% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

BNGO Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$28.5M-7.4%	$30.8M-14.8%	$36.1M+29.9%	$27.8M+54.6%	$18.0M+111.5%	$8.5M
Cost of Revenue	$15.3M-49.6%	$30.4M+14.5%	$26.6M+21.5%	$21.9M+54.9%	$14.1M+146.2%	$5.7M
Gross Profit	$13.2M+3369.7%	$380K-96.0%	$9.6M+60.9%	$5.9M+53.5%	$3.9M+39.7%	$2.8M
R&D Expenses	$11.4M-54.1%	$24.8M-54.1%	$54.0M+10.2%	$49.0M+118.1%	$22.5M+119.2%	$10.3M
SG&A Expenses	$35.1M-32.2%	$51.9M-44.1%	$92.8M+4.7%	$88.6M+51.5%	$58.5M+88.3%	$31.1M
Operating Income	-$33.3M+67.9%	-$104.0M+51.7%	-$215.2M-63.4%	-$131.7M-70.8%	-$77.1M-100.0%	-$38.6M
Interest Expense	N/A	N/A	$5.1M+1617.8%	$298K-67.9%	$927K-63.2%	$2.5M
Income Tax	$67K+103.0%	$33K-46.8%	$62K-96.7%	$1.9M+133.0%	-$5.7M-19813.8%	$29K
Net Income	-$26.4M+76.4%	-$112.0M+51.8%	-$232.5M-75.3%	-$132.6M-83.1%	-$72.4M-76.2%	-$41.1M
EPS (Diluted)	$-4.85	$-88.13+78.4%	$-408.60	$-4.58	$-0.26	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$6.7M-15.9%	$8.0M+7.9%	$7.4M+9.4%	$6.7M+4.3%	$6.5M-20.9%	$8.2M+34.4%	$6.1M-21.9%	$7.8M
Cost of Revenue	$3.4M-24.5%	$4.6M+13.9%	$4.0M+22.8%	$3.3M-7.5%	$3.5M-25.9%	$4.7M-67.3%	$14.5M+180.0%	$5.2M
Gross Profit	$3.3M-4.4%	$3.4M+0.9%	$3.4M-3.1%	$3.5M+18.3%	$2.9M-14.0%	$3.4M+140.5%	-$8.4M-426.7%	$2.6M
R&D Expenses	$3.1M-2.8%	$3.2M+13.5%	$2.8M-3.0%	$2.9M+23.7%	$2.4M-31.8%	$3.5M-26.3%	$4.7M-30.9%	$6.8M
SG&A Expenses	$8.0M-8.0%	$8.7M-3.9%	$9.1M+8.6%	$8.3M-7.6%	$9.0M-23.1%	$11.7M+24.1%	$9.5M-18.1%	$11.6M
Operating Income	-$7.9M+7.5%	-$8.5M0.0%	-$8.5M-9.5%	-$7.8M+7.9%	-$8.5M+29.1%	-$11.9M+72.8%	-$43.9M-158.0%	-$17.0M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$10K-72.2%	$36K+157.1%	$14K+40.0%	$10K+42.9%	$7K+600.0%	$1K-95.8%	$24K-7.7%	$26K
Net Income	-$8.3M-4.7%	-$7.9M+6.7%	-$8.5M-24.0%	-$6.9M-121.1%	-$3.1M+84.6%	-$20.1M+54.5%	-$44.2M-172.7%	-$16.2M
EPS (Diluted)	$-0.76	N/A	$-1.59+20.1%	$-1.99-73.0%	$-1.15	N/A	$-30.92-114.6%	$-14.41

BNGO Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$73.6M-4.0%	$76.7M-64.2%	$214.4M-30.3%	$307.5M-18.5%	$377.1M+523.8%	$60.5M
Current Assets	$45.4M+14.9%	$39.5M-71.8%	$140.1M-10.9%	$157.3M-42.3%	$272.4M+482.2%	$46.8M
Cash & Equivalents	$3.0M-67.4%	$9.2M-48.9%	$17.9M+252.5%	$5.1M-79.3%	$24.6M-36.1%	$38.4M
Inventory	$7.8M-41.0%	$13.3M-51.9%	$27.6M-7.3%	$29.8M+140.3%	$12.4M+273.7%	$3.3M
Accounts Receivable	$5.2M+9.4%	$4.8M-49.0%	$9.3M+32.7%	$7.0M+42.3%	$4.9M+77.8%	$2.8M
Goodwill	N/A	N/A	$0-100.0%	$77.3M+37.6%	$56.2M+682.9%	$7.2M
Total Liabilities	$29.2M-29.4%	$41.3M-65.1%	$118.2M+103.5%	$58.1M+45.3%	$40.0M+57.6%	$25.4M
Current Liabilities	$22.9M-38.6%	$37.3M-62.7%	$100.0M+178.8%	$35.9M+64.3%	$21.8M+144.2%	$8.9M
Long-Term Debt	N/A	N/A	N/A	N/A	$0-100.0%	$16.3M
Total Equity	$44.4M+25.6%	$35.4M-63.2%	$96.2M-61.4%	$249.4M-26.0%	$337.1M+860.9%	$35.1M
Retained Earnings	-$719.6M-3.8%	-$693.2M-19.3%	-$581.2M-66.7%	-$348.7M-61.4%	-$216.1M-50.4%	-$143.7M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$64.8M-11.9%	$73.6M-6.9%	$79.1M+4.0%	$76.0M-3.1%	$78.4M+2.3%	$76.7M-12.2%	$87.4M-32.5%	$129.4M
Current Assets	$39.0M-14.1%	$45.4M-7.0%	$48.8M+14.4%	$42.7M-5.0%	$44.9M+13.8%	$39.5M-15.9%	$47.0M-22.4%	$60.6M
Cash & Equivalents	$3.4M+14.5%	$3.0M-2.4%	$3.1M-14.0%	$3.6M-1.7%	$3.6M-60.5%	$9.2M+4.3%	$8.8M-15.6%	$10.4M
Inventory	$7.7M-1.8%	$7.8M-7.1%	$8.4M-18.3%	$10.3M-9.7%	$11.4M-14.0%	$13.3M-18.5%	$16.3M-29.7%	$23.1M
Accounts Receivable	$4.1M-20.5%	$5.2M+14.9%	$4.5M+29.6%	$3.5M+4.1%	$3.4M-29.4%	$4.8M-10.6%	$5.3M-15.0%	$6.3M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$27.3M-6.2%	$29.2M-0.4%	$29.3M-4.5%	$30.6M+1.4%	$30.2M-26.8%	$41.3M+7.3%	$38.5M-21.5%	$49.0M
Current Liabilities	$21.2M-7.5%	$22.9M-0.2%	$23.0M-5.0%	$24.2M-8.4%	$26.4M-29.3%	$37.3M+13.3%	$33.0M-11.4%	$37.2M
Long-Term Debt	$10.3M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$37.5M-15.7%	$44.4M-10.8%	$49.8M+9.8%	$45.4M-5.8%	$48.2M+36.2%	$35.4M-27.6%	$48.9M-39.2%	$80.3M
Retained Earnings	-$727.9M-1.2%	-$719.6M-1.1%	-$711.7M-1.2%	-$703.2M-1.0%	-$696.3M-0.4%	-$693.2M-3.0%	-$673.1M-7.0%	-$628.9M

BNGO Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$16.3M+76.3%	-$68.9M+44.9%	-$125.2M-0.3%	-$124.8M-73.5%	-$71.9M-87.7%	-$38.3M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	$0
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	-$38.3M
Investing Cash Flow	-$12.7M-117.3%	$73.8M+205.7%	$24.2M-70.8%	$82.8M+129.8%	-$278.1M-11249.5%	-$2.5M
Financing Cash Flow	$24.0M+275.7%	-$13.7M-112.0%	$113.8M+394.7%	$23.0M-93.2%	$336.1M+443.0%	$61.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$5.7M-36.9%	-$4.2M+29.5%	-$5.9M-69.7%	-$3.5M-26.2%	-$2.8M+57.5%	-$6.5M+51.1%	-$13.3M+36.6%	-$21.0M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$5.5M+36.1%	$4.0M+185.9%	-$4.7M-335.9%	$2.0M+114.1%	-$14.1M-569.3%	$3.0M+155.8%	-$5.4M-118.8%	$28.6M
Financing Cash Flow	$657K-59.0%	$1.6M-84.1%	$10.1M+585.9%	$1.5M-86.5%	$10.9M+180.0%	$3.9M-35.4%	$6.0M+404.4%	-$2.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

BNGO Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	46.3%+45.0pp	1.2%-25.3pp	26.5%+5.1pp	21.4%-0.2pp	21.5%-11.1pp	32.6%
Operating Margin	-117.0%+220.9pp	-337.9%+258.1pp	-596.0%-122.3pp	-473.7%-44.9pp	-428.8%+24.6pp	-453.4%
Net Margin	-92.6%+271.4pp	-364.0%+279.8pp	-643.7%-166.8pp	-476.9%-74.1pp	-402.8%+80.6pp	-483.4%
Return on Equity	-59.4%+257.2pp	-316.7%-74.9pp	-241.8%-188.6pp	-53.2%-31.7pp	-21.5%+95.7pp	-117.2%
Return on Assets	-35.9%+110.2pp	-146.1%-37.7pp	-108.4%-65.3pp	-43.1%-23.9pp	-19.2%+48.8pp	-68.0%
Current Ratio	1.98+0.9	1.06-0.3	1.40-3.0	4.38-8.1	12.47+7.2	5.23
Debt-to-Equity	0.66-0.5	1.17-0.1	1.23+1.0	0.23+0.2	0.00-0.5	0.47
FCF Margin	N/A	N/A	N/A	N/A	N/A	-450.6%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	48.6%+5.9pp	42.8%-3.0pp	45.7%-5.9pp	51.6%+6.1pp	45.5%+3.6pp	41.9%+180.9pp	-139.1%-172.3pp	33.3%
Operating Margin	-118.1%-10.7pp	-107.4%+8.5pp	-115.9%-0.0pp	-115.9%+15.2pp	-131.1%+15.2pp	-146.3%+576.6pp	-722.9%-503.9pp	-219.0%
Net Margin	-124.2%-24.4pp	-99.8%+15.6pp	-115.4%-13.6pp	-101.8%-53.8pp	-48.0%+198.5pp	-246.5%+482.0pp	-728.6%-519.8pp	-208.8%
Return on Equity	-22.2%-4.3pp	-17.9%-0.8pp	-17.1%-2.0pp	-15.1%-8.7pp	-6.4%+50.5pp	-56.9%+33.7pp	-90.5%-70.3pp	-20.2%
Return on Assets	-12.8%-2.0pp	-10.8%-0.0pp	-10.8%-1.7pp	-9.0%-5.1pp	-4.0%+22.3pp	-26.3%+24.4pp	-50.6%-38.1pp	-12.5%
Current Ratio	1.84-0.1	1.98-0.1	2.12+0.4	1.76+0.1	1.70+0.6	1.06-0.4	1.43-0.2	1.63
Debt-to-Equity	0.73+0.1	0.66+0.1	0.59-0.1	0.68+0.0	0.63-0.5	1.17+0.4	0.79+0.2	0.61
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

$24.4M

$5.1M

$19.9M

$21.2M

Frequently Asked Questions

What is Bionano Genomics Inc's annual revenue?

Bionano Genomics Inc (BNGO) reported $28.5M in total revenue for fiscal year 2025. This represents a -7.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Bionano Genomics Inc's revenue growing?

Bionano Genomics Inc (BNGO) revenue declined by 7.4% year-over-year, from $30.8M to $28.5M in fiscal year 2025.

Is Bionano Genomics Inc profitable?

No, Bionano Genomics Inc (BNGO) reported a net income of -$26.4M in fiscal year 2025, with a net profit margin of -92.6%.

What is Bionano Genomics Inc's EBITDA?

Bionano Genomics Inc (BNGO) had EBITDA of -$23.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Bionano Genomics Inc's gross margin?

Bionano Genomics Inc (BNGO) had a gross margin of 46.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Bionano Genomics Inc's operating margin?

Bionano Genomics Inc (BNGO) had an operating margin of -117.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Bionano Genomics Inc's net profit margin?

Bionano Genomics Inc (BNGO) had a net profit margin of -92.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Bionano Genomics Inc's return on equity (ROE)?

Bionano Genomics Inc (BNGO) has a return on equity of -59.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Bionano Genomics Inc's operating cash flow?

Bionano Genomics Inc (BNGO) generated -$16.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Bionano Genomics Inc's total assets?

Bionano Genomics Inc (BNGO) had $73.6M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Bionano Genomics Inc spend on research and development?

Bionano Genomics Inc (BNGO) invested $11.4M in research and development during fiscal year 2025.

How many shares does Bionano Genomics Inc have outstanding?

Bionano Genomics Inc (BNGO) had 11M shares outstanding as of fiscal year 2025.

What is Bionano Genomics Inc's current ratio?

Bionano Genomics Inc (BNGO) had a current ratio of 1.98 as of fiscal year 2025, which is generally considered healthy.

What is Bionano Genomics Inc's debt-to-equity ratio?

Bionano Genomics Inc (BNGO) had a debt-to-equity ratio of 0.66 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Bionano Genomics Inc's return on assets (ROA)?

Bionano Genomics Inc (BNGO) had a return on assets of -35.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Bionano Genomics Inc's cash runway?

Based on fiscal year 2025 data, Bionano Genomics Inc (BNGO) had $3.0M in cash against an annual operating cash burn of $16.3M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Bionano Genomics Inc's Piotroski F-Score?

Bionano Genomics Inc (BNGO) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Bionano Genomics Inc's earnings high quality?

Bionano Genomics Inc (BNGO) has an earnings quality ratio of 0.62x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Bionano Genomics Inc?

Bionano Genomics Inc (BNGO) scores 23 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.